Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2638

Sort by

Sort Order Select

Journal Articles

How I treat renal anemia

Steven Fishbane, Daniel W. Coyne

Blood (2020) 136 (7): 783–789.

https://doi.org/10.1182/blood.2019004330

Published: 2020

Journal Articles

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Blood (2020) 136 (1): 71–80.

https://doi.org/10.1182/blood.2019004460

Published: 2020

Includes: Supplemental data

Journal Articles

Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study

Blood (2020) 135 (21): 1833–1846.

https://doi.org/10.1182/blood.2019003807

Published: 2020

Includes: Supplemental data

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Christopher Melani, Elaine S. Jaffe, Wyndham H. Wilson

Blood (2020) 135 (16): 1344–1352.

https://doi.org/10.1182/blood.2019000933

Published: 2020

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

Heme A1M’ed at the kidney in sickle cell disease

Santosh L. Saraf

Blood (2020) 135 (13): 979–981.

https://doi.org/10.1182/blood.2020005134

Published: 2020

Journal Articles

Targeting Critical Kinases and Anti-Apoptotic Molecules Overcomes Steroid Resistance in Infant MLL-Rearranged Leukemia

Anne Pieta De Groot, Yoriko Saito, MD, Eiryo Kawakami, Mari Hashimoto, Yuki Aoki, Rintaro Ono, MD PhD, Ikuko Ogahara, Saera Fujiki, Akiko Kaneko, Takashi Watanabe, PhD, Masatoshi Takagi, MD PhD, Daisuke Tomizawa, MD PhD, Katsuyoshi Koh, MD, Mariko Eguchi, MD, Eiichi Ishii, MD PhD, Osamu Ohara, Leonard Shultz, PhD, Shuki Mizutani, Fumihiko Ishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 3885.

https://doi.org/10.1182/blood-2019-129719

Published: 2019

Journal Articles

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Tapan M. Kadia, MD, Gautam M. Borthakur, MD, Elias Jabbour, MD, Marina Y Konopleva, MD PhD, Farhad Ravandi, MD, Courtney D. DiNardo, MDMSc, Daniella Zheleva, PhD, David Blake, PhD, Judy H Chiao, MD

Blood (2019) 134 (Supplement_1): 3926.

https://doi.org/10.1182/blood-2019-131930

Published: 2019

Journal Articles

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 3836.

https://doi.org/10.1182/blood-2019-128853

Published: 2019

Journal Articles

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Courtney D. DiNardo, MDMSc, Rebecca Olin, MDMS, Jo Ishizawa, MD PhD, Hiroyuki Sumi, PhD, Jingdong Xie, PhD, Kazunobu Kato, MD PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3932.

https://doi.org/10.1182/blood-2019-122241

Published: 2019

Journal Articles

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Shelby Sloan, BS, Fiona Brown, BS, JI Hyun Chung, PhD, Alexander Prouty, BS, Esther Wheeler, BS, Bonnie K Harrington, DVM, PhD, Eric Brooks, BS, Ayse S Yilmaz, MS, Hatice G Ozer, PhD, John C. Byrd, MD, Selina Chen-Kiang, PhD, Maurizio Di Liberto, PhD, Rosa Lapalombella, PhD, Kris Vaddi, PhD, Peggy Scherle, PhD, Youssef Youssef, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4065.

https://doi.org/10.1182/blood-2019-128998

Published: 2019

Journal Articles

Real Life CNS-IPI Score Validation: A Retrospective Analysis of Two Centers in Brazil Outside of Clinical Trial

Thais Fischer, MD, Natalia Pin Chuen Zing, MD, Sérgio Costa Fortier, MD, Talita Silveira, Carlos Sérgio Chiattone, MD

Blood (2019) 134 (Supplement_1): 4133.

https://doi.org/10.1182/blood-2019-125576

Published: 2019

Journal Articles

Hemopexin Replacement Therapy Protects Sickle Cell Disease Mice from Acute Kidney Injury

Samit Ghosh, Oluwaseun Orikogbo, Rimi Hazra, Bethany Flage, Danielle Crosby, Solomon Fiifi Ofori-Acquah

Blood (2019) 134 (Supplement_1): 78.

https://doi.org/10.1182/blood-2019-127161

Published: 2019

Journal Articles

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Amandeep Godara, MD, Denis Toskic, BS, Benjamin Rosenthal, BS, Cindy Varga, MD BSc, Adin Kugelmass, BSc, Ping Zhou, MD PhD, Teresa Fogaren, NP, Raymond L Comenzo, MD

Blood (2019) 134 (Supplement_1): 4369.

https://doi.org/10.1182/blood-2019-127004

Published: 2019

Journal Articles

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Sneha Purvey, MD, Kenneth Seier, MS, Sean M. Devlin, PhD, Josel D Ruiz, MPH, Molly A. Maloy, MS, Gunjan L. Shah, MDMS, Hani Hassoun, MD, Sergio A. Giralt, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 4577.

https://doi.org/10.1182/blood-2019-129195

Published: 2019

Journal Articles

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Shayna Sarosiek, John Mark Sloan, MD, Karen Quillen, MDMPH, Dina Brauneis, ANP, Ramon Cruz, Amanda Schulman, Salli Fennessey, Anthony Shelton, Vaishali Sanchorawala, MD

Blood (2019) 134 (Supplement_1): 4578.

https://doi.org/10.1182/blood-2019-129095

Published: 2019

Journal Articles

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Faye Amelia Sharpley, BA MA MSc MBBChir FRCPath, Hannah Victoria Giles, FRCPath, MRCP, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Carol J Whelan, Philip N Hawkins, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 4375.

https://doi.org/10.1182/blood-2019-128175

Published: 2019

Journal Articles

Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen

Joshua A Fein, MD, Avichai Shimoni, MD, Ivetta Danylesko, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Guy Chowers, MD, Zachary Cohen, Arnon Nagler, MD MSc, Roni Shouval

Blood (2019) 134 (Supplement_1): 4489.

https://doi.org/10.1182/blood-2019-126325

Published: 2019

Journal Articles

Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia

Santosh L. Saraf, MD, Vimal K. Derebail, MD, Xu Zhang, PhD, Mark T Gladwin, MD, Victor R Gordeuk, MD, Jane A. Little, MD

Blood (2019) 134 (Supplement_1): 2268.

https://doi.org/10.1182/blood-2019-124737

Published: 2019

NARROW

How I treat renal anemia

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study

AL patients don’t dare go without dara

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Erdheim-Chester disease

Heme A1M’ed at the kidney in sickle cell disease

Targeting Critical Kinases and Anti-Apoptotic Molecules Overcomes Steroid Resistance in Infant MLL-Rearranged Leukemia

An Oral Combination Study of Novel Nucleoside Analogue Sapacitabine and BCL2 Inhibitor Venetoclax to Treat Patients with Relapsed or Refractory AML or MDS

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Targeting PRMT5 to Circumvent Acquired Ibrutinib Resistance in Mantle Cell Lymphoma

Real Life CNS-IPI Score Validation: A Retrospective Analysis of Two Centers in Brazil Outside of Clinical Trial

Hemopexin Replacement Therapy Protects Sickle Cell Disease Mice from Acute Kidney Injury

In Systemic Light-Chain Amyloidosis Complete and Very Good Partial Responses Are Not Enough: Involved Free Light Chain (iFLC) Levels < 10mg/L Are Associated with Optimal Long-Term Survival

Difference in Involved and Uninvolved Free Light Chain (dFLC) of Less Than 1mg/DL Early Post Risk Adapted Melphalan and Autologous Stem Cell Transplantation (RA-ASCT) Predicts Renal Response at 1 Year in Light Chain (AL) Amyloidosis

Safety and Efficacy of Propylene Glycol-Free Melphalan (Evomela) in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Preliminary Results of a Phase II Study

Quantitative Immunoprecipitation Free Light Chain Mass Spectrometry (QIP-FLC-MS) Simplifies Monoclonal Protein Assessment and Provides Added Clinical Value in Systemic AL Amyloidosis

Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen

Manifestations of Reduced Kidney Function Occur at a Higher Estimated Glomerular Filtration Rate in Sickle Cell Anemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only